Previous 10 | Next 10 |
Summary Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Four additional studies are expected to have data releases in 2023; GLEAM/GLIMMER/DAYLIGHT/GLOW. Kodiak will onl...
Summary Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3. Strong financial position could lead the company into high level future growth. Vertex can reach an annualized return of...
As the year draws to a close, it's safe to say that investors won't look back at 2022 fondly. All three major U.S. market indexes are deep in the red, the economy isn't great, and geopolitical tensions persist. But some corporations have defied the odds and delivered solid returns this year...
An expert panel of the European Medicines Agency (EMA) has recommended issuing marketing authorization for Sanofi ( NASDAQ: SNY ) ( OTCPK:SNYNF ) to include the skin disorder prurigo nodularis as a use of injectable prescription medicine Dupixent. Prurigo nodularis (PN...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis PR Newswire Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life i...
Update 1:30pm: Adds that PTAB also ruled patent '338 was unpatenable. Regeneron ( NASDAQ: REGN ) pared gains after the U.S. Patent Trial and Appeal Board ruled that patent claims to treat retinal diseases was unpatenable. The PTAB ruled that Regeneron Eylea patent '3...
Regeneron ( NASDAQ: REGN ) pared gains after the U.S. Patent Trial and Appeal Board ruled that a patent to treat retinal diseases was unpatenable. The PTAB ruled that Regeneron Eylea patent '069 was unpatenable, according to a ruling o n the agency's website. Morgan ...
Summary AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its pla...
The US FDA has approved an additional indication for Regeneron Pharmaceuticals' ( NASDAQ: REGN ) Libtayo , this time as a first-line treatment in advanced non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy. The indication is for patients...
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) PR Newswire Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...